<!-- Generated with --reviewer claude (real Claude Opus 4.8, claude-opus-4-8).
     Every quote the reviewer cites is re-verified verbatim against its source;
     the BRIM-3 next-source suggestion carries no quote because it is not in the corpus. -->

# Claim Audit Report

## Claim
> BRAF V600E melanoma is associated with response to targeted inhibitor treatment.

## Audit Verdict
**contested** (strength +0.00) — supports: 1×clinical; conflicts: 1×clinical; 2 indirect

## Evidence Map
- Independent sources: 1 supporting, 1 conflicting
- Sentences: 1 supporting · 1 conflicting · 2 indirect
- Records retrieved: 3
- Coverage by claim entity:
  - BRAF (gene): 1 supporting, 1 conflicting [toy-002, toy-006]
  - melanoma (disease): 1 supporting, 1 conflicting [toy-002, toy-006]
  - targeted therapy (drug_class): 1 supporting, 1 conflicting [toy-002, toy-006]

## Supporting Evidence
- [high | clinical | toy-002@0-116] This sample record describes BRAF V600E melanoma as a setting where targeted inhibitors can produce tumor responses.

## Conflicting Evidence
- [high | clinical | toy-006@0-150] This synthetic record describes a small cohort where BRAF status was not associated with durable response to targeted inhibitor treatment in melanoma.

## Indirect / Insufficient Evidence
- [medium | clinical | toy-001@0-136] In this toy abstract, EGFR activating variants are associated with response to tyrosine kinase inhibitors in non-small cell lung cancer.
- [medium | clinical | toy-001@137-285] Acquired resistance is described after first-line inhibitor exposure, and follow-up testing is needed to identify resistance-associated alterations.

## Citation Audit
- 2/2 cited quotes are verbatim spans of their source (100% faithful).

## Overclaim Flags
- None.

## Contradiction Flags
- 🟡 Evidence conflicts: 1 supporting vs 1 conflicting independent source(s).

## Retrieval Gaps
- None.

## Reviewer Critique (claude)
_The verdict of 'contested' is defensible but the two cited sources are synthetic toy records explicitly labeled as such ('The abstract is synthetic and intended for retrieval testing only'), so they cannot support a real biomedical claim. The apparent conflict is also weaker than the contradiction flag suggests: toy-006 concerns 'durable response' (and BRAF status generally, not specifically V600E), whereas toy-002 concerns 'tumor responses' (initial, not durable). These are not directly contradictory endpoints, so labeling them as head-to-head conflicting is an overclaim. The two 'indirect' sources include toy-001, which is about EGFR/NSCLC and irrelevant to BRAF melanoma._
- **weak-citation:** Supporting source is explicitly synthetic and not real evidence; cannot substantiate a clinical claim. [toy-002: “The abstract is synthetic and intended for retrieval testing only.”]
- **weak-citation:** Conflicting source is also explicitly synthetic and flagged as needing manual review; not usable as real counter-evidence. [toy-006: “The result is presented as conflicting toy evidence and would require manual review in a real literature workflow.”]
- **overclaim:** The 'conflict' conflates two different endpoints: toy-006 addresses durable response while toy-002 addresses initial tumor response. Initial response and durable response are not contradictory, so the contradiction flag overstates the tension. [toy-006: “BRAF status was not associated with durable response to targeted inhibitor treatment in melanoma”]
- **weak-citation:** toy-006 references 'BRAF status' broadly, not specifically V600E, so its relevance to the V600E-specific claim is indirect. [toy-006: “a small cohort where BRAF status was not associated with durable response”]
- **missing-counter-evidence:** One of the 'indirect' sources is about EGFR variants in NSCLC and has no bearing on BRAF V600E melanoma; it should not be counted as relevant indirect evidence. [toy-001: “EGFR activating variants are associated with response to tyrosine kinase inhibitors in non-small cell lung cancer”]
- **next-source:** Pull a real pivotal trial: the BRIM-3 vemurafenib phase III RCT (Chapman et al., NEJM 2011) in BRAF V600E metastatic melanoma, which directly tests response/survival benefit and would replace synthetic placeholders.

## What Would Change My Mind?
- An independent, well-powered study on BRAF, melanoma and targeted therapy that breaks the tie, plus a mechanism explaining why the existing reports disagree.

## Suggested Next Checks
- Review cited records manually before drawing scientific conclusions.
- Add model-based claim extraction with citation-grounded outputs.
- Evaluate evidence support with a curated benchmark.

## Limitations
- Uses toy/sample abstracts by default; optional PubMed mode uses public metadata.
- Deterministic stance labeling is a scaffold for a future model-backed extractor.
- Evidence labels are illustrative research signals, not clinical guidance.
- Research signal only — not medical advice, not a validated clinical assessment.
